Phase II clinical study of SHR8008 for acute vulvovaginal candidiasis (VVC)
Latest Information Update: 13 Oct 2021
Price :
$35 *
At a glance
- Drugs Oteseconazole (Primary)
- Indications Vulvovaginal candidiasis
- Focus Therapeutic Use
- 13 Oct 2021 New trial record